The U.S. National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines（ACTIV-4）initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19. The majority of patients who have died from COVID-19 developed blood clots. Blood thinners keep blood cells from turning into clumps or sticking to each other. But doctors don’t know which ones are best to use or what dose is most effective at treating COVID-19. NIH will evaluate varying doses of blood thinners with 3 groups of adults diagnosed with COVID-19.
The trials will be conducted at more than 100 sites around the world and will provide critical insights that could help guide the care of patients with COVID-19, particularly those who suffer from life-threatening blood clots.